Therapy Areas: Central Nervous System
QB3953 enters into new partnership with Toray, Japan
2 August 2017 -

San Francisco-based biotech company QB3953 said on Tuesday that it has formed a new partnership with Toray in Japan to pursue breakthroughs in the treatment of neurological diseases.

Under the terms of the partnership, Toray will utilise QB3953's lab space to collaborate with US academia and to develop small-molecule drugs to treat chronic itch, pain and neurodegenerative disease. It will be offering seminars and office hours, bringing insight from across the Pacific to the labs of Bay Area entrepreneurs.

The arrangement provides Toray with the opportunity to nurture its pharmaceutical enterprise, while bringing new expertise and trans-Pacific relationships to QB3953's research community.

Pursuant to the partnership, Toray will focus on identifying new drug targets for the treatment of chronic itch, pain and neurodegenerative diseases, when successful, could attenuate abnormal signal transduction, ceasing the itchy and painful sensation and accumulation of harmful substances in central nervous system.

QB3953's fully equipped laboratories allows enterprising researchers to greatly accelerate their R&D and substantially lower their capital requirements. The incubator's 24,000 square foot lab and office building is home to 40 of the Bay Area's most promising biotech startups. It provides state-of-the-art facilities, including a core facility with millions of dollars worth of equipment, administrative support, skilled laboratory technicians, seminars and a community of entrepreneurial scientists.

Login
Username:

Password: